Length of Ischemic Time Is Critical for Accurate Determination of Homologous Recombination Capacity by Immunofluorescence Staining in Ovarian Cancer Formalin-Fixed Paraffin-Embedded Samples
Context.—: Tubo-ovarian high-grade serous carcinomas (HGSC) that are deficient in homologous recombination (HR) are more sensitive to poly ADP-ribose polymerase (PARP) inhibitors than their HR-proficient counterparts. To target PARP inhibitors to the right patients, HR status must be accurately determined. Functional HR (fHR) assays, which assess HR status by quantifying RAD51, are promising approaches for identifying HR-deficient cases. However, these tests have yet to be optimized for pre-analytical variables and tissue properties that may impact RAD51 quantification. Objective.—: To establish how typical pre-analytical variables (ischemic time, formalin fixation, and ethanol storage) and tissue-level necrosis and hypoxia affect read-outs of fHR capacity, with systematic evaluation of prolonged ischemic time. Additionally, biological (intra-tumor) variation in fHR measurements was assessed. Design.—: The immunofluorescence-based fHR assay was performed on a retrospective and a prospectively collected cohort of formalin-fixed paraffin-embedded HGSC specimens with varying pre-analytical and tissue-level conditions. Intra-tumor variation in fHR capacity was assessed in multiple tumor areas and independent tumor pieces. Results.—: Prolonged ischemic time led to a substantial reduction in nuclear RAD51 signal, resulting in lower fHR scores and false fHR deficiency calls. The other examined variables did not significantly impact fHR scores. Intra-tumor variation in fHR scores was low, and the fHR category, when determined from different regions of the same tumor, remained unchanged. Conclusions.—: Prolonged ischemic time adversely affects fHR assay performance, highlighting the importance of monitoring and documenting sample handling processes, particularly in HGSC, and warrants caution when interpreting fHR results from archival tumor material for which such information is unavailable.
Authors
- Ulla‐Maija Haltia (ORCID: https://orcid.org/0000-0003-1629-6400)
- Johanna Hynninen (ORCID: https://orcid.org/0000-0002-0854-7225)
- Ezgi Karagöz (ORCID: https://orcid.org/0000-0001-6522-0088)
- Matilda Salko (ORCID: https://orcid.org/0000-0003-2548-8017)
- Liisa Kauppi (ORCID: https://orcid.org/0000-0002-6759-8997)
- Anni Virtanen (ORCID: https://orcid.org/0000-0002-7467-8434)
- Sanna Pikkusaari (ORCID: https://orcid.org/0000-0002-2966-0446)
- Jaana Oikkonen (ORCID: https://orcid.org/0000-0002-1063-2736)
- Sakari Hietanen (ORCID: https://orcid.org/0000-0003-4734-4743)
- Anni Härkönen
- Anniina Färkkilä
- Srividhya Sundaresan (ORCID: https://orcid.org/0009-0000-6984-1332)
- Minna R. Eriksson (ORCID: https://orcid.org/0009-0001-4168-9911)
- Heini Lassus
- Anna Kanerva
- Manuela Tumiati
- Johanna Tapper
- Titta Joutsiniemi
- Riitta Koivisto-Korander
- Heidi Koskela
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Institute for Molecular Medicine Finland (FI)
- Hospital District of Helsinki and Uusimaa (FI)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5858/arpa.2025-0479-oa
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- Helsingin Yliopisto
- European Commission
- Syöpäsäätiö
- Helsinki Institute of Life Science, Helsingin Yliopisto